Skip to search formSkip to main contentSkip to account menu

lifitegrast

Known as: (2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid, L-phenylalanine, n-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)- 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

Ophthalmic SolutionPhenylalanineSulfones

Narrower (1)

SAR 1118
analogs & derivativeslifitegrast 50 MG/ML Ophthalmic Solutionlifitegrast 50 MG/ML Ophthalmic Solution [Xiidra]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
Abstract Five randomized, double-masked, placebo-controlled trials were conducted in the US in adults with DED, an eye dryness… 
2018
2018
Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease.
Studies have shown that lifitegrast will reduce the symptoms of dry eye disease in some patients, although the benefit is… 
2018
2018
Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report
Background: To describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR… 
2018
2018
Mechanisms of Action of the Leukocyte Function-Associated Antigen-1 (LFA-1) Antagonist Lifitegrast in Dry Eye Disease (DED)
2017
2017
Ocular distribution and pharmacokinetics of lifitegrast following repeat topical ocular dose administration to pigmented rabbits
2017
2017
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: combined evidence from 5 randomized controlled trials.
2016
2016
Shire gets FDA nod for Xiidra (lifitegrast) for dry eye
Shire plc obtained U.S. Food and Drug Administration (FDA) approval for Xiidra (lifitegrast ophthalmic solution) 5%, a twice… 
2014
2014
Lifitegrast yields treatment benefit across symptom endpoints
A phase III clinical trial of lifitegrast 5% ophthalmic solution for treatment of dry eye showed treatment benefit across all… 
2013
2013
Lifitegrast misses prespecified co-primary endpoint
Shire has announced the results from OPUS-2, a phase III efficacy and safety study of its treatment of dry eye, 5.0% lifitegrast… 
2012
2012
SARcode reports phase III results for lifitegrast
SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)